

Acute Coronary Syndrome in Women: An Overview

Briana T. Costello, MD
George A. Younis, MD

For decades, cardiovascular disease—specifically, myocardial infarction (MI)—was thought to be a disease of men. The major acute coronary syndrome (ACS) trials that guide daily clinical practice disproportionately enrolled men, thus promoting this fallacy. Fortunately, the medical literature and the lay media have increasingly recognized that heart disease is the primary cause of death in women and that cardiovascular disease has no sex preference.

Traditional cardiac risk factors of diabetes, smoking, obesity, and hypertension affect the cardiovascular system differently in men and women.¹ In the INTERHEART study of more than 27,000 patients, diabetes increased risk in women 4-fold, but only 2.5-fold in men. In a 12-year follow-up to a Norwegian epidemiologic study, smoking increased a woman's risk more than a man's (relative risk, 3.3 vs 1.9), especially in women 35 to 44 years old (relative risk, 7.1 vs 2.3).² Women are thought to be protected from cardiovascular disease, particularly coronary artery disease, by endogenous estrogen, which has wide-ranging effects throughout the circulatory system.³ Estrogen positively affects the cholesterol profile by increasing high-density lipoproteins and decreasing low-density lipoproteins.⁴ Estrogen also relaxes smooth muscle cells, leading to lower blood pressure, and is thought to assist in the body's clearance of cellular free radicals that may otherwise increase inflammatory processes and promote cardiovascular disease.⁵

Loss of the beneficial estrogen effect after menopause may help explain why women present later in life with cardiovascular disease, particularly ACS. Interestingly, replacing estrogen after menopause has not proved beneficial and actually increases cardiovascular risk (both arterial and venous).⁶ In the GUSTO IIb (Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes) trial, women who presented with ACS were older and more likely than men to have diabetes, hypertension, and congestive heart failure.^{7,8} However, after 70 years of age, these differences became less pronounced, thus supporting the loss-of-estrogen theory.⁹

Women and men with ACS may present with different symptoms. In a large review of patients with ACS, 37% of women and 27% of men reported no chest pain.¹⁰ Women more often reported upper back, neck, or jaw pain; dyspnea; and weakness.

Not recognizing symptoms often delays diagnosis of ACS. However, even after diagnosis, women are less likely than men to be referred for coronary angiography, percutaneous intervention, and fibrinolysis, which delays definitive treatment for many and places the myocardium at further risk. Women also receive less intensive medical therapy both during and after an ACS event. These sex-related factors cumulatively have lasting effects, and post-ACS outcomes are consistently poorer in women than in men.¹¹

The pathophysiology of ACS may also differ by sex. Plaque erosion is the most frequent cause of ACS in women; in men, it is plaque rupture.¹² Plaque erosion is seen on intravascular imaging in up to one third of women with ACS, even when no lesions are identifiable angiographically.¹² Plaque rupture, in contrast, is more easily identifiable angiographically.¹² Spontaneous coronary artery dissection (SCAD), an uncommon cause of ACS, occurs almost exclusively in women. In a prospective cohort of patients with SCAD, more than 90% of patients were female; in addition, 25.7% of all patients presented with ST-segment-elevation MI, and 74.3% presented with non-ST-segment-elevation MI.¹³ A high degree of suspicion for SCAD is crucial in women with ACS because immediate medical therapy may provide better outcomes than percutaneous coronary intervention.¹³ Although there is no consensus on medical therapy for SCAD, most women are treated with aspirin and β -blockers. This

★ CME Credit

Presented at the 9th Annual Women's Heart & Vascular Symposium, Texas Heart Institute, Houston, 26 January 2019.

Section Editor:

Stephanie A. Coulter, MD

Key words: Acute coronary syndrome; coronary artery dissection; spontaneous; myocardial infarction; risk factors; sex factors

From: Center for Women's Heart & Vascular Health (Dr. Costello) and Department of Cardiology (Dr. Younis), Texas Heart Institute, Houston, Texas 77030

Address for reprints:

George A. Younis, MD,
6560 Fannin St., Suite 1750,
Houston, TX 77030

E-mail: gyounis@gmail.com

© 2020 by the Texas Heart®
Institute, Houston

combination can lower the risk of recurrence, but in approximately 10% of patients, it will not prevent it.¹³

Meanwhile, the medical community continues to raise awareness of cardiovascular disease as the leading cause of death and an important driver of morbidity and mortality in both sexes, with a growing emphasis on the need to study its effects in women. Recognizing sex disparities in the diagnosis and treatment of cardiovascular disease is of the utmost importance.

References

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364(9438):937-52.
2. Njølstad I, Arnesen E, Lund-Larsen PG. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction. A 12-year follow-up of the Finnmark Study. *Circulation* 1996;93(3):450-6.
3. Yang XP, Reckelhoff JF. Estrogen, hormonal replacement therapy and cardiovascular disease. *Curr Opin Nephrol Hypertens* 2011;20(2):133-8.
4. García L, Hernández I, Cervera Aguilar R, Ayala AR. Effects of estrogens and progestogens on the lipid profile in postmenopausal hypogonadism [in Spanish]. *Ginecol Obstet Mex* 2001;69:351-4.
5. Ashraf MS, Vongpatanasin W. Estrogen and hypertension. *Curr Hypertens Rep* 2006;8(5):368-76.
6. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288(3):321-33.
7. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction [published erratum appears in *N Engl J Med* 1997;337(4):287]. *N Engl J Med* 1997;336(23):1621-8.
8. Doshi SB, Agarwal A. The role of oxidative stress in menopause. *J Midlife Health* 2013;4(3):140-6.
9. Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. *JAMA* 2012;307(8):813-22.
10. Canto JG, Goldberg RJ, Hand MM, Bonow RO, Sopko G, Pepine CJ, Long T. Symptom presentation of women with acute coronary syndromes: myth vs reality. *Arch Intern Med* 2007;167(22):2405-13.
11. Jneid H, Fonarow GC, Cannon CP, Hernandez AF, Palacios IF, Marea AO, et al. Sex differences in medical care and early death after acute myocardial infarction. *Circulation* 2008;118(25):2803-10.
12. White SJ, Newby AC, Johnson TW. Endothelial erosion of plaques as a substrate for coronary thrombosis. *Thromb Haemost* 2016;115(3):509-19.
13. Saw J, Humphries K, Aymong E, Sedlak T, Prakash R, Starovoytov A, Mancini GBJ. Spontaneous coronary artery dissection: clinical outcomes and risk of recurrence. *J Am Coll Cardiol* 2017;70(9):1148-58.